Abstract
The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS- CoV-2) is our latest pandemic and has turned out to be a global public health crisis. One of the special characteristics of this disease is that it may predispose patients to thrombotic disease both in the venous and arterial circulation. We review arterial and venous thromboembolic complications in patients with COVID-19, epidemiology, pathogenesis, hematologic biomarkers, and current antithrombotic strategies. Future perspectives and clinical trials are ongoing to determine the best thromboprophylaxis strategies in the hospitalized patients with severe COVID-19.
Keywords: COVID-19, thrombosis, thromboembolism, venous thromboembolism, thromboprophylaxis, bleeding, stroke, myocardial infarction, pulmonary embolism.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives
Volume: 21 Issue: 1
Author(s): Juan J. Rodriguez, Oscar C. Munoz*, Mateo Porres-Aguilar and Debabrata Mukherjee
Affiliation:
- Department of Interventional Cardiology, Del Sol Medical Center, El Paso, TX 79925,United States
Keywords: COVID-19, thrombosis, thromboembolism, venous thromboembolism, thromboprophylaxis, bleeding, stroke, myocardial infarction, pulmonary embolism.
Abstract: The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS- CoV-2) is our latest pandemic and has turned out to be a global public health crisis. One of the special characteristics of this disease is that it may predispose patients to thrombotic disease both in the venous and arterial circulation. We review arterial and venous thromboembolic complications in patients with COVID-19, epidemiology, pathogenesis, hematologic biomarkers, and current antithrombotic strategies. Future perspectives and clinical trials are ongoing to determine the best thromboprophylaxis strategies in the hospitalized patients with severe COVID-19.
Export Options
About this article
Cite this article as:
Rodriguez J. Juan , Munoz C. Oscar *, Porres-Aguilar Mateo and Mukherjee Debabrata , Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives, Cardiovascular & Hematological Disorders-Drug Targets 2021; 21 (1) . https://dx.doi.org/10.2174/1871529X21666210315123347
DOI https://dx.doi.org/10.2174/1871529X21666210315123347 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Endothelial Dysfunction in Cardiac Allograft Vasculopathy: Potential Pharmacological Interventions
Current Vascular Pharmacology Safety of Dabigatran in an Elderly Population: Single Center Experience in Italy
Current Drug Safety Assessments of Immunomodulatory and Inflammatory effects against Induction of Entamoeba histolytica (HM1 IMS strain) crude extract Antigen in Complete Freund’s Adjuvant Induced Rheumatoid Arthritis Female Wistar Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Triple Antithrombotic Therapy vs. Double Antithrombotic Therapy: One Scenario, 8 Questions, Many Conclusions
Current Cardiology Reviews Metallocarboxypeptidases: Emerging Drug Targets in Biomedicine
Current Pharmaceutical Design Direct Thrombin Inhibitors for Treatment of Heparin Induced Thrombocytopenia, Deep Vein Thrombosis and Atrial Fibrillation
Current Pharmaceutical Design Properties and Clinical Development of a Novel Coating Technology: The poly[bis(trifluoroethoxy)phosphazene]
Recent Patents on Drug Delivery & Formulation Activated Protein C: A Promising Drug with Multiple Effects?
Mini-Reviews in Medicinal Chemistry One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Awareness and Perception of Thromboembolism and Thromboprophylaxis among Hospitalized Patients in Jordan
Current Clinical Pharmacology Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Leech Thrombin Inhibitors
Current Pharmaceutical Design Editorial [Hot Topic: Latest Developments in Pharmaceutical Design of Arachidonic Acid Metabolites: Prostaglandins, Thromboxanes, Hepoxilins and Isoprostanes (Executive Editors: J.-M. Dogne and K.-H. Ruan )]
Current Pharmaceutical Design Antithrombotic Therapy After TAVR
Current Vascular Pharmacology Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets